GNOM


Genomics & Biotechnology ETF

Reasons to Consider GNOM

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Structural Tailwinds

The cost of genomic sequencing has dropped from nearly $100mm per genome in 2002 to less than $1,000 in 2020. Adoption has continued to rise, as costs plummet.1

Targeted Exposure

GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

1National Human Genome Research Institute, Nov 2021

Key Information As of 01/19/22

Inception Date 04/05/19
Total Expense Ratio 0.50%
Net Assets $200.56 million
NAV $16.03
Fact Sheet

ETF Summary

The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

ETF Objective

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

Trading Details As of 01/19/22

Ticker GNOM
Bloomberg Index Ticker SOLGNOM
CUSIP 37954Y434
ISIN US37954Y4347
Primary Exchange Nasdaq
Shares Outstanding 12,510,000
Number of Holdings 40
30-Day Median Bid-Ask Spread 0.25%

Distributions As of 01/19/22

30-Day SEC Yield -0.37%
Distribution Frequency Semi-Annually

ETF Prices As of 01/19/22

NAV $16.03 Daily Change -$0.18 -1.08%
Market Price $16.07 Daily Change -$0.17 -1.05%

Performance History

As of recent month & quarter-end (12/31/21)
As of recent month & quarter-end (12/31/21)
Fund NAV Market Price Index
1 Year -16.00% -15.93% -15.65%
Since Inception 10.02% 10.85% 10.57%
1 Year -16.00% -15.93% -15.65%
Since Inception 10.02% 10.85% 10.57%
Year-to-Date -16.00% -15.93% -15.65%
1 Month -3.85% -3.47% -3.84%
3 Months -10.62% -10.80% -10.50%
Since Inception 29.86% 32.55% 31.72%
Year-to-Date -16.00% -15.93% -15.65%
1 Month -3.85% -3.47% -3.84%
3 Months -10.62% -10.80% -10.50%
Since Inception 29.86% 32.55% 31.72%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings As of 01/19/22

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
6.69 BMRN BIOMARIN PHARMAC 2437071 86.00 156,012 13,417,032.00
5.20 QGEN QIAGEN N.V. BYXS688 49.79 209,353 10,423,685.87
5.14 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 3.90 2,644,818 10,302,744.31
5.05 A AGILENT TECHNOLOGIES INC 2520153 140.43 72,058 10,119,104.94
4.65 ARWR ARROWHEAD PHARMA BYQBFJ8 53.79 173,488 9,331,919.52
4.56 RARE ULTRAGENYX PHARM BJ62Z18 66.75 137,023 9,146,285.25
4.56 SRPT SAREPTA THERAPEUTICS INC B8DPDT7 63.15 144,782 9,142,983.30
4.05 ALNY ALNYLAM PHARMACE B00FWN1 138.62 58,525 8,112,735.50
3.86 CRSP CRISPR THERAPEUTICS AG BDHF4K6 64.19 120,571 7,739,452.49
3.74 MYGN MYRIAD GENETICS INC 2614153 26.68 280,905 7,494,545.40
3.60 NTLA INTELLIA THERAPEUTICS INC BYZM6C2 83.67 86,322 7,222,561.74
3.56 VRTX VERTEX PHARM 2931034 230.84 30,902 7,133,417.68
3.35 VCYT VERACYTE INC BFTWZY0 27.22 246,564 6,711,472.08
3.10 CDNA CAREDX INC BP3YM74 37.46 165,906 6,214,838.76
2.99 NTRA NATERA INC BYQRG48 61.17 98,138 6,003,101.46
2.88 GILD GILEAD SCIENCES INC 2369174 69.07 83,728 5,783,092.96
2.65 NSTG NANOSTRING TECHN BBL59X6 32.03 165,993 5,316,755.79
2.60 ILMN ILLUMINA INC 2613990 384.36 13,566 5,214,227.76
2.53 EDIT EDITAS MEDICINE INC BZ8FPH3 19.93 254,090 5,064,013.70
2.33 PACB PACIFIC BIOSCIEN B4N8MH9 10.66 438,498 4,674,388.68
2.32 NVTA INVITAE CORP BVVCNT1 11.16 416,335 4,646,298.60
2.24 SRNE SORRENTO THERAPEUTICS INC BCT5QQ7 4.31 1,044,293 4,500,902.83
1.98 RCKT ROCKET PHARMACEU BDFKQ07 17.23 230,580 3,972,893.40
1.78 4974 JP TAKARA BIO INC B03ML21 20.77 171,874 3,570,060.78
1.77 RGNX REGENXBIO INC BZ0G875 26.17 135,605 3,548,782.85
1.62 BNTX BIONTECH SE-ADR BK6H543 161.66 20,049 3,241,121.34
1.44 ALLO ALLOGENE THERAPEUTICS INC BFZNYB7 11.68 247,705 2,893,194.40
1.42 MRNA MODERNA INC BGSXTS3 174.07 16,390 2,853,007.30
1.35 SGMO SANGAMO THERAPEUTICS INC 2573083 6.02 449,201 2,704,190.02
1.32 QURE UNIQURE NV BJFSR88 18.62 141,740 2,639,198.80
1.00 CRBU CARIBOU BIOSCIENCES INC BNYJR68 11.33 176,459 1,999,280.47
0.92 BLUE BLUEBIRD BIO INC BBFL7S1 7.55 245,430 1,852,996.50
0.82 TSVT 2SEVENTY BIO INC BMTXV88 20.17 81,788 1,649,663.96
0.57 PRQR PROQR THERAPEUTICS NV BQRX1W2 6.25 183,957 1,149,731.25
0.56 CLLS CELLECTIS - ADR BWFKZT2 6.70 167,558 1,122,638.60
0.46 DTIL PRECISION BIOSCIENCES INC BJ0M2S0 5.10 181,914 927,761.40
0.34 ADVM ADVERUM BIOTECHN BD6NXD7 1.59 422,174 671,256.66
0.32 ZIOP ZIOPHARM ONCOLOGY INC B0HZZ46 0.90 719,569 644,805.78
0.25 FIXX HOMOLOGY MEDICINES INC BFMMJ23 3.47 144,889 502,764.83
0.23 WVE WAVE LIFE SCIENCES LTD BYZG9R0 2.51 182,552 458,205.52
0.22 CASH 1.00 443,217 443,205.36
Holdings are subject to change.

Country Breakdown As of 12/31/21

Country Weight (%)
United States 80.6
Netherlands 6.5
China 4.7
Switzerland 3.7
Germany 2.1
Japan 1.6
France 0.6
Singapore 0.2

Source: AltaVista Research, LLC

ETF Characteristics As of 01/19/22

Return on Equity -31.90%
Weighted Avg. Market Cap 14,826 M
2020 2021
Price-to-earnings -15.99 -21.16
Price-to-book value 5.80 8.09

Source: AltaVista Research, LLC

ETF Risk Stats As of 01/19/22

Versus Beta
S&P 500 0.97
MSCI EAFE 0.91
MSCI Emg. Mkts 0.98
Standard Deviation 30.40%

Source: AltaVista Research, LLC

ETF Research

View More Related Research

Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.